Clinical effect of folic acid in the treatment of primary hypertension in young people
Objective To study the clinical effect of folic acid in the treatment of primary hypertension in young people.Methods A total of 200 young patients with primary hypertension who were admitted to the Emergency Department of Dongguan People's Hospital from March 2022 to February 2023 were selected as the research object and divided into the control group and the intervention group according to the lottery method,with 100 patients in each group.The control group was treated with routine therapy,while the intervention group was treated with folic acid on the basis of routine therapy.The blood biochemical indexes after treatment,carotid intima-media thickness and carotid atherosclerotic lesion volume before and after treatment,end-diastolic ventricular septal thickness,left ventricular end-diastolic dimension and left ventricular end-diastolic posterior wall thickness after treatment,and blood pressure levels of young patients with different methylenetetrahydrofolate reductase(MTHFR)and methionine synthase reductase(MTRR)genotypes before and after treatment were compared between the two groups.Results After treatment,all blood biochemical indexes in the intervention group were better than those in the control group,with the difference was statistically significant(P＜0.05).Before and after treatment,there was no difference between the two groups in carotid intima-media thickness and carotid atherosclerotic lesion volume(P＞0.05).After treatment,the end-diastolic ventricular septal thickness,left ventricular end-diastolic dimension and left ventricular end-diastolic posterior wall thickness of the intervenient group were better than those of the control group,with the difference was statistically significant(P＜0.05).There was no significant difference between diastolic blood pressure and systolic blood pressure in young patients with primary hypertension of MTHFR wild type(MTHFR 667CC type),MTHFR heterozygous mutant type(MTHFR 667CT type),MTHFR homozygous mutant type(MTHFR 667T type),MTRR 66-locus(MTRR 66G)type and MTRR genotype(MTRR A66G type)genotypes before treatment(P＞0.05).After treatment,the blood pressure levels of patients with five genotypes were lower than those before treatment,and the difference was statistically significant(P＜0.05).The diastolic blood pressure and systolic blood pressure of MTHFR 667CC and MTRR 66G after treatment were lower than those of MTHFR 667CT,MTHFR 667TT and MTRR A66G,and the difference was statistically significant(P＜0.05).However,there was no significant difference in diastolic blood pressure and systolic blood pressure between MTHFR 667CC and MTRR 66G after treatment(P＞0.05).Conclusion Folic acid has a high clinical value in the treatment of primary hypertension in young people.It can control the patients'blood pressure and stabilize various blood biochemical indexes,which is beneficial to improve the carotid intima-media thickness and carotid atherosclerosis,providing high degree of protection against the targeted damage of heart and brain.Therefore,it is worth popularizing.
Folic acidPrimary hypertension in young peopleCarotid intima-media thicknessCarotid atherosclerosis
万方数据
维普
